- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01869062
Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography (SonR-ECHO)
The main objective of the SONR-ECHO trial is to demonstrate that optimization of CRT parameters by SonR technology is able to increase the rate of CRT-D responders, based on significant LV reverse remodeling, as compared to Standard of Care settings.
This study will also evaluate the effectiveness of CRT-D SonR system as compared to Standard of care (SoC) programming methods in providing appropriate LV filling, as expected from the Ritter method.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the effectiveness of CRT-D SonR system as compared to SoC programming methods to:
- Increase the rate of patients responding to CRT
- Provide appropriate hemodynamic cardiac effect, as expected from the Ritter method.
The identification of CRT responders, as defined by echocardiography, generally refers to a significant reduction of the LV End-Systolic Diameter (LVESD) and/or LVESV during Follow-Up (FUp).
Patients will be considered as responders to CRT if their LVESV decreased by > 15% after 6 months of CRT therapy as compared to baseline. The percentage of CRT responders will be compared between the two study arms.
SoC is defined as the standard CRT system programming/optimization method currently used by physicians in study centers and any method may be used in the study if considered as routine practice in the study center.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Québec, Canada, G1V 4G5
- Institut Universitaire de Cardiologie et Pneumologie de Québec
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible for implantation of a CRT-D device according to published relevant ESC and CCS guidelines ;
- In Sinus Rhythm;
- Have reviewed, signed and dated an informed consent
Exclusion Criteria:
- Previous implant with a pacemaker, an Implantable Cardioverter-Defibrillator or a CRT device (except upgrade from single chamber ICD with a fully functional defibrillation lead not under recall or surveillance);
- Persistent atrial arrhythmias (or cardioversion for Atrial Fibrillation) within the past month;
- Ventricular tachyarrhythmia secondary to reversible causes such as acute myocardial infarction (MI), digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;
- Incessant ventricular tachyarrhythmia;
- Unstable angina, or acute MI, Coronary Artery Bypass-Grafting (CABG), or Percutaneous Transluminal Coronary Angioplasty (PTCA) within the past 4 weeks;
- Correctable valvular disease that is the primary cause of heart failure;
- Mechanical heart valve or indication for valve repair or replacement;
- Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the previous 3 months);
- Post heart transplant (patients who are waiting for a heart transplant are allowed in the study);
- Already included in another clinical study that could confound the results of this study;
- Life expectancy less than 1 year;
- Inability to understand the purpose of the study;
- Unavailability for scheduled follow-up or refusal to cooperate;
- Sensitivity to 1 mg Dexamethasone Sodium Phosphate (DSP);
- Age of less than 18 years;
- Pregnancy;
- Drug addiction or abuse;
- Under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: SonR CRT Optimization 'On'
CRT-D device with the SonR optimization algorithm programmed being 'on'.
|
Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
|
Other: SonR CRT Optimization 'Off'
CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
|
Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CRT-responders rate increase based on LVESV decrease at M6 / baseline
Time Frame: 6 months
|
For the purpose of this study, CRT-responders are defined as patients experiencing a decrease in LVESV of 15% or more at M6 Fup as most clinical trials used. The main objective of the SONR-ECHO trial is to show a minimum increase of CRT-responders rate of 15% (up to 72% or more) in the SonR study group as compared to SoC arm. |
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A-wave truncation assessment at M6
Time Frame: 6 months
|
The Ritter's method attempts to optimize AV and VV timings in dual-chamber PM patients.
According to this method, AV delay is optimal when LVFT is maximal and mitral valve closure only occurs after atrial systole (A-wave) is complete.
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Report LV remodeling from LVEDV decrease at M6 / baseline
Time Frame: 6 months
|
LVEDV is a standard marker of CRT effectiveness.
Echocardiographic data collected at M6 FUp will document the evolution of LVEDV as compared to baseline in order to assess CRT effectiveness.
|
6 months
|
LVEF increase at M6
Time Frame: 6 months
|
LVEF, as a surrogate of LVESV and LVEDV, is a standard marker of CRT effectiveness.
Echocardiographic data collected at M6 FUp will document the evolution of LVEF as compared to baseline in order to assess CRT effectiveness.
|
6 months
|
AF analysis during FUp
Time Frame: 6 months
|
Sorin commercialized CRT-D device offering both SonR optimization algorithm and atrio biventricular provides a performing Mode Switch (MS) function able to store and document sustained AF episodes during FUp. The MS data stored inSorin commercialized CRT-D device offering both SonR optimization algorithm and atrio biventricular memories will be collected at each FUp in order to report total AF burden, permanent AF and AF event free-rate in both arms up to M6 FUp. |
6 months
|
AF-related events
Time Frame: 6 months
|
Number of AF-events per patients, the event type, time to the first occurrence, the survival (event-free) curves will be reported per study group.
|
6 months
|
LA and RV functions
Time Frame: 6 months
|
Echocardiographic data from each exam will be analyzed in order to report the evolution of the diastolic and systolic functions of the LA and of the RV per study group.
|
6 months
|
Adverse events
Time Frame: 6 months
|
All AEs observed during FUp in all study patients will be classified by origin, symptoms, severity, treatment and outcome per study arm.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: François Philippon, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICSY01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
Clinical Trials on SonR CRT Optimization 'On'
-
MicroPort CRMSorin CRMUnknownHeart Failure NYHA Class III and Ambulatory IVUnited States, Spain, United Kingdom, Germany, Italy, Australia, Netherlands, Portugal, France, Austria, Switzerland, Slovenia
-
MicroPort CRMSorin CRMUnknownHeart Failure (NYHA Class III and Ambulatory IV)United States
-
LivaNovaCompleted
-
Maria Vittoria HospitalCompleted
-
Sheba Medical CenterCompletedCongestive Heart FailureIsrael
-
Henry Ford Health SystemCentral Arkansas Veterans Healthcare SystemTerminatedRight Bundle-Branch BlockUnited States
-
Alan J. Bank, MDMedtronicCompleted
-
MicroPort CRMCompletedTachycardiaSpain, United States, United Kingdom, France, Japan, Germany, Italy
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR); Abbott Medical DevicesTerminated
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingCongenital Heart Disease | Transposition of Great Vessels | Congenitally Corrected Transposition of the Great Arteries | Systemic Right Ventricle | Heart Failure CongenitalFrance